Bleeding Complications after Basilar Artery Fibrinolysis with Tissue Plasminogen Activator

References

1. ↵
   Hacke W, Ringelstein EB. Local intraarterial thrombolysis in vertebrobasilar thromboembolic disease. AJNR Am J Neuroradiol 1983;4:401-404

   Abstract/FREE Full Text
2. Hacke W, Zeumer H, Ferbert A, Bruckmann H, del Zoppo GJ. Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke 1988;19:1216-1222

   Abstract/FREE Full Text
3. ↵
   Zeumer H, Freitag HJ, Zanella F, Thie A, Arning C. Local intra-arterial fibrinolytic therapy in patients with stroke: urokinase versus recombinant tissue plasminogen activator (r-TPA). Neuroradiology 1993;35:159-162

   CrossRefPubMedWeb of Science
4. Becker KJ, Monsein LH, Ulatowski J, et al. Intraarterial thrombolysis in vertebrobasilar occlusion. AJNR Am J Neuroradiol 1996;17:255-262

   Abstract
5. Brandt T, von Kummer R, Muller-Kuppers M, Hacke W. Thrombolytic therapy of acute basilar artery occlusion: variables affecting recanalization and outcome. Stroke 1996;27:875-881

   Abstract/FREE Full Text
6. ↵
   Cross DT, Moran CJ, Akins PT, Angtuaco EE, Diringer MN. Relationship between clot location and outcome after basilar artery thrombolysis. AJNR Am J Neuroradiol 1997;18:1221-1228

   Abstract
7. Cross DT, Moran CJ, Akins PT, Angtuaco EE, Derdeyn CP, Diringer MN. Collateral circulation and outcome after basilar artery thrombolysis. AJNR Am J Neuroradiol 1998;:1557-1563
8. Wijdicks EFM, Nichols DA, Thielen KR, et al. Intra-arterial thrombolysis in acute basilar artery thromboembolism: the initial Mayo Clinic experience. Mayo Clin Proc 1997;72:1005-1013

   CrossRefPubMedWeb of Science
9. ↵
   United States Food and Drug Administration. Letter to Healthcare Providers.. Washington, DC: Food and Drug Administration; January 25, 1999
10. Abbott Laboratories. Letter to Abbokinase Customers.. N Chicago, IL: Abbott Laboratories; April 5, 1999
11. ↵
    Henze T, Boeer A, Terbe U, Romatowski J. Lysis of basilar artery occlusion with tissue plasminogen activator. Lancet 1987;2:1391
12. Overgaard K, Pedersen H, Boesen J, et al. Thrombolytic therapy of cerebral arterial occlusion with recombinant tissue plasminogen activator. Neurol Res 1990;12:78-80

    PubMed
13. ↵
    Wolpert S, Bruckmann H, Greenlee R, et al. Neurological evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. AJNR Am J Neuroradiol 1993;35:159-162
14. Terada T, Yokote H, Tsuura M, et al. Tissue plasminogen activator thrombolysis and transluminal angioplasty in the treatment of basilar artery thrombosis: case report. Surg Neurol 1994;41:358-361

    CrossRefPubMedWeb of Science
15. Jansen O, von Kummer R, Forsting M, et al. Thrombolytic therapy in acute occlusion of the intracranial internal carotid artery bifurcation. AJNR Am J Neuroradiol 1995;16:1977-1986

    Abstract
16. Oezbek C, Heisel A, Voelk M, et al. Management of stroke complicating cardiac catheterization with recombinant tissue-type plasminogen activator. Am J Cardiol 1995;76:733-738

    CrossRefPubMed
17. von Kummer R, Holle R, Rosen L, et al. Does arterial recanalization improve outcome in carotid territory stroke? Stroke 1995;26:581-587

    Abstract/FREE Full Text
18. Sandoval A, Laufer N. Thromboembolic stroke complicating coronary intervention: acute evaluation and management in the cardiac catheterization laboratory. Cathet Cardiovasc Diag 1998;44:412-414

    PubMed
19. Lewandowski CA, Frankel M, Tomsick TA, et al. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute stroke. Stroke 1999;30:2598-2605

    Abstract/FREE Full Text
20. ↵
    Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-1025

    CrossRefPubMedWeb of Science
21. ↵
    The NINDS rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587

    CrossRefPubMedWeb of Science
22. ↵
    Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS study, a randomized controlled trial: alteplase thrombolysis for acute noninterventional therapy in acute stroke. JAMA 1999;282:2019-2026

    CrossRefPubMedWeb of Science
23. ↵
    Working Party on Thrombolysis in the Management of Limb Ischemia. Thrombolysis in the management of lower limb peripheral arterial occlusion: a consensus document. Am J Cardiol 1998;81:207-218

    CrossRefPubMedWeb of Science
24. ↵
    Collen D, DeCock F, Demarsin E, Lijnen HR, Stump DC. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro. Thromb Haemost 1986;56:35-39

    PubMedWeb of Science
25. ↵
    Duffy MJ. Urokinase-type plasminogen activator and malignancy. Fibrinolysis 1993;7:295-302

    CrossRef
26. ↵
    Physicians' Desk Reference. 53rd ed. Medical Economics Company; Montvale, NJ: 1999
27. ↵
    Adams HP, Bogousslavsky J, Polzer J, Barnathan E, Leclerc JR. A dose escalation study of abciximab in acute ischemic stroke. Presented at the 72nd scientific session of the American Heart Association, Atlanta, Georgia, November 1999
28. ↵
    del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke 1998;29:4-11

    Abstract/FREE Full Text
29. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke: the PROACT II study, a randomized controlled trial. JAMA 1999;282:2003-2011

    CrossRefPubMedWeb of Science